First cardiovascular event in patients with type 2 diabetes mellitus of a cardiovascular risk management program of a poor Colombian population: a cohort study

Table 1 Baseline Characteristics by history of Type 2 DM before and after propensity Matching cohort

	Before propensity matching (N = 56,351)			After propensity matching (N = 36,898)
n(%) / mean(±sd)	No T2DM	T2DM	P	No T2DM	T2DM	P
Women	24,495	13,299	< 0.001	12,741	12,644	0.276
Women	66.23	68.66		69.06	68.53
Age	65.50 (+ − 13.66)	63.24 (+ − 13.08)	< 0.001	63.7 (+ − 13.5)	63.8 (+ − 13.0)	0.7186
Hypertension	36,444	17,998	< 0.001	17,915	17,935	0.531
Hypertension	98.54	92.93		97.11	97.21
Dyslipidemia	31,323	16,685	< 0.001	15,956	15,983	0.680
Dyslipidemia	84.7	86.15		86.49	86.63
Obesity	14,323	9700	< 0.001	9278	9315	0.700
Obesity	38.73	50.08		50.29	50.49
Controlled Hypertension	33,096	17,582	< 0.001	16,652	16,702	0.377
Controlled Hypertension	89.49	90.78		90.26	90.53
CKD	5440	3184	< 0.001	3040	3034	0.933
CKD	14.71	16.44		16.48	16.45
Number of antihypertensive drugs	0.72 (+ − 0.44)	0.67 (+ − 0.46)	< 0.001	1.81(+ − 1.66)	1.82(+ − 1.8)	0.227
ACEI-ARB	24,218	12,126	< 0.001	12,075	12,072	0.974
ACEI-ARB	65.48	62.61		65.45	65.43
Antiplatelet	12,957	7492	< 0.001	7242	7347	0.264
Antiplatelet	35.04	38.68		39.25	39.82
Calcium Antagonists	9943	5878	< 0.001	5776	5817	0.646
Calcium Antagonists	26.89	30.35		31.31	31.53
Statins	15,624	9672	< 0.001	9323	9382	0.539
Statins	42.25	49.94		50.53	50.85
Insulin	0	3418	< 0.001	0	3222	< 0.001
Insulin	0	17.65		0	17.46
Human Insulin	0	1604	< 0.001	0	1497	< 0.001
Human Insulin	0	8.28		0	8.11
Analogous Insulin	0	2503	< 0.001	0	2375	< 0.001
Analogous Insulin	0	12.92		0	12.87
Sulfonylureas	0	5852	< 0.001	0	5548	< 0.001
Sulfonylureas	0	30.21		0	30.07
Metformin	0	8430	< 0.001	0	7950	< 0.0010
Metformin	0	43.53		0	43.09
DPP4-I	0	677	< 0.001	0	648	< 0.001
DPP4-I	0	3.5		0	3.51
GLP1 receptor agonists	0	88	< 0.001	0	85	< 0.001
GLP1 receptor agonists	0	0.45		0	0.46

ISSN: 1471-2261